Auxilium

BioFlorida Appoints Mark A. Glickman as President & CEO to Continue to Propel Florida's Life Sciences Community Forward

Retrieved on: 
Monday, December 4, 2023
Auxilium, Esperion Therapeutics, Sale, Principal, Esperies, Negotiation, Research, Therapy, Patient, MBA, Retirement, PALM, Growth, Hospira, Human, Management, Fine chemical, Capitol

WEST PALM BEACH, Fla., Dec. 4, 2023 /PRNewswire/ -- BioFlorida, the leading voice of Florida's life sciences industry, announced that Mark A. Glickman, MBA, will serve as its new President and Chief Executive Officer.

Key Points: 
  • WEST PALM BEACH, Fla., Dec. 4, 2023 /PRNewswire/ -- BioFlorida, the leading voice of Florida's life sciences industry, announced that Mark A. Glickman, MBA, will serve as its new President and Chief Executive Officer.
  • A longstanding member of Florida's life sciences community, Mr. Glickman brings over 30 years of experience and leadership to BioFlorida.
  • "We are thrilled to welcome Mark Glickman as BioFlorida's new President and CEO," said Robert Finizio, Chairman of the Board for BioFlorida.
  • Mark Glickman will officially assume the role of President and CEO of BioFlorida on December 9, 2023.

Masimo Announces New Member of the Board of Directors

Retrieved on: 
Tuesday, November 7, 2023
Medical Devices, Health, Technology, Health Technology, Cardiology, Auxilium, Pharmacia, Mayo Collaborative Services v. Prometheus Laboratories, Inc., BICO Group, Catalent, Chemical engineering, MASI, Chemical substance, Vice, Business, Perrigo, Central Executive Committee of the Pakistan Peoples Party, Merck Millipore, Supervisory board, Gothenburg University Library, Executive Committee, University of Gothenburg, Gothenburg School of Business, Economics and Law, Retirement, Management, Engineering

Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.
  • Mr. Classon is an experienced medical technology executive and board member.
  • Mr. Classon was previously Chairman of the Board of Directors of Perrigo Company plc, Chairman of the Board of Directors of Tecan Group Ltd., Chairman of the Board of Directors of Hill-Rom Corporation, and Chairman of the Board of Directors of Auxilium Pharmaceuticals, Inc.
  • Joe Kiani, Chairman and CEO of Masimo, said, “We’re happy to welcome Rolf to our Board.

NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.

Retrieved on: 
Monday, November 6, 2023
Auxilium, GCGR, Research and Development Council of New Jersey, Research, Medical college, IND, Glucagon-like peptide-1 receptor, Physician, GPR119, GSK plc, Development, Oxyntomodulin, Endo International, Ferring Pharmaceuticals, Johns Hopkins, NASH, Medicine, Biology, Ursinus College, OXM, Obstetrics, Tursi, Drexel University College of Medicine, GLP1R, Chemistry, Fatty liver disease, Bachelor of Science in Human Biology, Johns Hopkins Hospital, Investigational New Drug, Pharmaceutical industry, Gynaecology

Dr. Tursi will also serve as a member of the Board's Nominating and Corporate Governance Committee.

Key Points: 
  • Dr. Tursi will also serve as a member of the Board's Nominating and Corporate Governance Committee.
  • "James is a proven leader, with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience," stated Andrew I. Koven, Chairman of NeuroBo's Board of Directors.
  • As such, I look forward to working closely with the NeuroBo leadership team and my fellow Directors to maximize the potential for the Company's next generation pharmaceuticals to treat cardiometabolic diseases."
  • Previously, from April 2020 until January 2022, Dr. Tursi was Chief Scientific Officer U.S. for Ferring Pharmaceuticals.

Wealth Management Industry Embraces an AI-Powered Future of Abundance and Growth at Fearless Investing Summit in Miami

Retrieved on: 
Tuesday, October 3, 2023
Technology, Finance, Fintech, Consulting, Banking, Professional Services, Software, Data Analytics, Asset Management, Artificial Intelligence, Kraken, Auxilium, Insurance, Lead management, RIA, Reward, Fearless, Documentation, Risk, CRMS, The White Glove, Auxilium Pallacanestro Torino, Growth, CIO, AI, Salesforce, FMG, Financial adviser, Pharmaceutical industry, Nitrogen

Nitrogen (formerly Riskalyze), the company that is revolutionizing how financial advisors and wealth management firms grow, today announced major enhancements to its growth platform and painted a cohesive vision of the AI-powered future of abundance for advisors at the company’s annual Fearless Investing Summit .

Key Points: 
  • Nitrogen (formerly Riskalyze), the company that is revolutionizing how financial advisors and wealth management firms grow, today announced major enhancements to its growth platform and painted a cohesive vision of the AI-powered future of abundance for advisors at the company’s annual Fearless Investing Summit .
  • The event brings together leaders from firms representing thousands of advisors from across the wealth management industry as well as the entire spectrum of supporting wealthtech.
  • “The conversation and community at the Fearless Investing Summit this week reinforced my belief that we’re at a huge and exciting inflection point as a wealth management profession,” said Aaron Klein , chief executive officer at Nitrogen.
  • For more information or for a demo of the Nitrogen Growth Platform, please visit NitrogenWealth.com/growth-platform .

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors

Retrieved on: 
Friday, May 12, 2023
Auxilium, Glucagon-like peptide-1 receptor, OXM, Union of Sales and Marketing Professionals, Medical device, Senior, International Management Institute, Bhubaneswar, NASH, Esperion Therapeutics, Marketing, Abbott Laboratories, State university system, Business, Head, Sale, Political science, Esperies, Business administration, Investigational New Drug, GCGR, New York University Stern School of Business, GPR119, GLP1R, Sales and operations planning, Fatty liver disease, Growth, Commercial, Therapy, IND, Oxyntomodulin, Student Senators Council of New York University, Endo International, Pharmaceutical industry, Management

"Mark is a highly accomplished pharmaceutical industry executive with more than 30 years of industry experience, including many senior leadership positions," said Andrew I. Koven, Chairman of NeuroBo's Board of Directors.

Key Points: 
  • "Mark is a highly accomplished pharmaceutical industry executive with more than 30 years of industry experience, including many senior leadership positions," said Andrew I. Koven, Chairman of NeuroBo's Board of Directors.
  • "I am excited to join the NeuroBo Board of Directors at such an important stage for the Company, especially during the advancement of the Company's two promising cardiometabolic assets," said Mr. Glickman.
  • "I look forward to working with my fellow Directors and the NeuroBo leadership team as we position the Company for long-term growth and value creation."
  • Prior to this role, he served as Chief Business Officer, Commercial of TherapeuticsMD, Inc. since June 2021.

Alladapt Appoints Louise Peacock as Chief Regulatory Affairs and Quality Officer

Retrieved on: 
Monday, May 1, 2023
Auxilium, OIT, University, Therapy, Food allergy, Marketing, Pharmacovigilance, Abbott, Peanut allergy, University of West London, Patient, Immunoglobulin E, FDA, Pharmaceutical industry, Circassia, Pharmacology

MENLO PARK, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, today announced the appointment of Louise Peacock as Chief Regulatory Affairs and Quality Officer, effective May 1, 2023.

Key Points: 
  • MENLO PARK, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, today announced the appointment of Louise Peacock as Chief Regulatory Affairs and Quality Officer, effective May 1, 2023.
  • Ms. Peacock joins Alladapt with more than three decades of experience in global regulatory affairs, including instrumental contributions to the approval of Palforzia® - the first and only FDA approved oral immunotherapy (OIT) to treat peanut allergy.
  • “I am delighted to welcome Louise, who brings focused expertise in global regulatory affairs and an impressive track record of securing regulatory approvals for innovative therapeutics over the course of her career,” said Ashley Dombkowski, Ph.D., Alladapt’s Chief Executive Officer and co-founder.
  • “Louise’s expertise in the field of food allergy, coupled with her broad range of skills in regulatory affairs, pharmacovigilance and clinical science, will play a crucial role in shaping our clinical and regulatory strategy.

Biote Names John Denne as General Manager, Men’s Health Division

Retrieved on: 
Monday, April 10, 2023
Biotechnology, General Health, Health, Auxilium, Male, Trade, Hormone replacement therapy, Roche, Marketing, Endo International, Denne, Environmental Health Divisions, Bristol, Growth, Bristol Myers Squibb, Commercial, Pharmaceutical industry, Jacques Biot

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has joined the Company as General Manager, Men’s Health Division.

Key Points: 
  • Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has joined the Company as General Manager, Men’s Health Division.
  • In this role, Denne will lead Biote’s sales initiatives to expand the Company’s presence in the growing market for male hormone replacement therapy.
  • A healthcare industry veteran, Denne joins Biote with more than 30 years of experience in sales, business development, strategic marketing and management.
  • “We’re thrilled to have John join the Biote team as we strengthen our focus on serving the men’s hormone replacement therapy market,” said Terry Weber, Biote Chief Executive Officer.

Icon Health Joins Auxilium Health Network to Address Beneficiaries' Growing Orthopedic Needs

Retrieved on: 
Thursday, February 16, 2023
Auxilium, CMS, Acos, PCP, MSK, Thought, Health, Risk, Medicare, ACO, Holy Child Auxilium School, Octane Fitness, LLC v. ICON Health & Fitness, Inc., Patient, Partnership, Nursing, Icon

STAMFORD, Conn., Feb. 16, 2023 /PRNewswire/ -- Icon Health, a leading value-based orthopedic services and care management provider, has announced an agreement with Auxilium Health Network, a CMS ACO REACH participant, to provide comprehensive orthopedic services to Medicare beneficiaries.

Key Points: 
  • STAMFORD, Conn., Feb. 16, 2023 /PRNewswire/ -- Icon Health, a leading value-based orthopedic services and care management provider, has announced an agreement with Auxilium Health Network, a CMS ACO REACH participant, to provide comprehensive orthopedic services to Medicare beneficiaries.
  • "Primary care has long been the focus of total cost of care arrangements," said Duncan Sibson, CEO of Icon Health.
  • Our agreement with Auxilium Health Network will allow us to do just that for orthopedic patients, who represent a top three spend category for ACOs."
  • Chris Tsang, CEO of Auxilium Health Network stated: "We are very excited to welcome Icon Health as a partner within our network to offer whole-person, comprehensive musculoskeletal care, as well as partner with Auxilium's PCPs.

Novita Pharmaceuticals Appoints Alan Wills as Its Chief Executive Officer

Retrieved on: 
Monday, February 13, 2023
Auxilium, Strategic management, Transgene (company), Master of Business Administration, Boston Consulting Group, Trial of the century, Stanford University, Canada Steamship Lines, Pfizer, Harvard Business School, Boston, Hospital, Business administration, Bristol Myers Squibb, Lucile Packard Children's Hospital, Business development, Medication, Pharmaceutical industry, Management, UnitedHealth Group

NEW YORK, Feb. 13, 2023 /PRNewswire-PRWeb/ -- Novita Pharmaceuticals, Inc. ("Novita" or the "Company"), a privately held clinical-stage pharmaceutical company dedicated to developing novel cancer drugs based on its proprietary fascin inhibitor technology, today announced that the Company's Board of Directors has appointed Alan Wills as its Chief Executive Officer.

Key Points: 
  • Novita Pharmaceuticals, Inc. ("Novita" or the "Company"), a privately held clinical-stage pharmaceutical company dedicated to developing novel cancer drugs based on its proprietary fascin inhibitor technology, today announced that the Company's Board of Directors has appointed Alan Wills as its Chief Executive Officer.
  • NEW YORK, Feb. 13, 2023 /PRNewswire-PRWeb/ -- Novita Pharmaceuticals, Inc. ("Novita" or the "Company"), a privately held clinical-stage pharmaceutical company dedicated to developing novel cancer drugs based on its proprietary fascin inhibitor technology, today announced that the Company's Board of Directors has appointed Alan Wills as its Chief Executive Officer.
  • Mr. Wills joined Novita as Chief Executive Officer on February 6, 2023, bringing extensive experience in the global biopharmaceutical industry, notably in business development, corporate strategy, M&A and licensing, and alliance management.
  • "We are delighted to have recruited a talent like Alan," said Dr. Jillian Zhang, President and Chief Scientific Officer, and a co-founder of Novita.

Blue Foundry Bancorp Names Elizabeth Varki Jobes, Esq. to Board of Directors

Retrieved on: 
Thursday, January 5, 2023
Auxilium, Therapy, Spark Therapeutics, Merck Serono, Rutgers Law School, Law, Blue, Senior, Management, Cephalon

RUTHERFORD, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Blue Foundry Bancorp (Nasdaq: BLFY) (the “Company”), announced today the appointment of Elizabeth Varki Jobes, Esq.

Key Points: 
  • RUTHERFORD, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Blue Foundry Bancorp (Nasdaq: BLFY) (the “Company”), announced today the appointment of Elizabeth Varki Jobes, Esq.
  • James D. Nesci, President and Chief Executive Officer stated, “We are excited to welcome Ms. Jobes to Blue Foundry’s Board of Directors.
  • She currently serves on the board of Ampio Pharmaceuticals, a public company, as well as the board of a private biopharmaceutical company (Eyam Vaccines and Immunotherapeutics), and the board of a not-for-profit organization.
  • Ms. Jobes is a member of the South Asian Bar Association and was a former board member of Women’s Way.